Consuming cannabis and magic mushrooms together can be a lot of fun. Marijuana’s effects can alter those of psilocybin so as to create a more pleasant overall experience for the user. It is important to remember that the kind of cannabis you consume, when exactly you consume it, and how potent it is, will all affect the trip you have. Knowing what effects to expect, and how to handle them, can make the whole experience more safe and pleasant.
At first glance, cannabis is suggested to “intensify the mushroom experience,” though also may “cloud” the psilocybin adventure. The timing of mixing the two also seems to play a role, with different outcomes depending on the progression of the trip. Ultimately, the conclusion seems to be that experience with both substances is a substantial advantage to obtaining positive outcomes.
To better understand the interwoven effects of mixing two different substances, it’s best to have a clear picture of what each accomplishes on its own. When it comes to psychoactive chemicals, every person will have their own experience; the expectations and results explained here are only a suggestion.
Cannabis and psilocybin mushrooms both contain multiple active ingredients. Cannabis contains hundreds of cannabinoids and terpenes.
Psilocybin mushrooms contain a cocktail of active molecules, including at least eight different psilocybin derivatives like baeocystin, norbaeocystin, serotonin, and aeruginascin.
The cannabis industry has recently learned that many of the lesser known active ingredients (e.g., CBD, CBC, CBG, THCv, etc.) in cannabis can be more valuable than THC, which was once believed to be the only molecule worth studying.
The compound CBD specifically may be helpful in countering the negative effects of mushroom usage. It has been considered to reduce the “jitters,” balancing the effects of THC in reducing disorientation, tachycardia, and eventual drowsiness. This may be due to the data that has shown it to act as a serotonin receptor activator.
The two active compounds have further been implicated in reducing nausea induced by many things, whether it be disease or other substances. The multitude of other compounds may provide a plethora of effects as well, depending on the personal metabolism and physiology of the user.
The Experience: Generally considered to be a “downer.” Attributed to CBD, especially prevalent in Indica species. Creates a “high” or “stoned” feeling, a general change in perception, heightened mood, and an increase in appetite.
The Downsides: A decrease in short-term memory, dry mouth, impaired motor skills, red eyes, and feelings of paranoia or anxiety.
Shrooms, at least the most common Psilocybe cubensis, usually contain relatively consistent levels of psilocybin and psilocin, the active compounds of “magic mushrooms.” Few other chemicals found in mushrooms are currently suspected to contribute to the subjective experience.
Considered an “upper” (similar to a sympathetic arousal state) though may also produce a “body high”. Characterized by euphoria, visual and mental hallucinations, changes in perception, a distorted sense of time, spiritual experiences, giddiness, joy, open and closed eye visuals (common at medium to high doses), along with synesthesia (e.g. hearing colours and seeing sounds). The mind-altering effects of psilocybin typically last from two to six hours.
The Downsides: Possible adverse reactions such as nausea and panic attacks, about a third of users report feelings of anxiety or paranoia. Feelings of disorientation, lethargy, and depression. Tachycardia, dilated pupils, restlessness or arousal, increased body temperature, headache, sweating and chills.
Shrooms and Cannabis
Both Cannabis and Psilocybin Mushrooms are naturally occurring organisms. They live and grow in nature. Each plant or mushroom produces its own cocktail of chemical compounds — cannabinoids, terpenes, psilocybin derivatives, etc.
In general, mixing cannabis and shrooms is considered to intensify the experience by triggering more abstract or thought-provoking visuals and sensations. This can be especially apparent near the end of a mushroom experience, prolonging the related visuals and changes in perception. THC-rich strains, primarily C. sativa, may assist in providing extra energy and positivity. CBD-rich strains, primarily C. indica, may assist in reducing nausea and limiting anxiety or “jitters.”
Cannabis and psilocybin mushrooms both contain multiple active ingredients. Cannabis contains hundreds of cannabinoids and terpenes. Psilocybin mushrooms contain a cocktail of active molecules, including at least eight different psilocybin derivatives like baeocystin, norbaeocystin, serotonin, and aeruginascin.
Psilocybin is still universally described as “the” (sole) active ingredient in magic mushrooms. (Notably, psilocybin is not actually the active ingredient. Rather psilocybin is a prodrug of psilocin, which provides the psychedelic effects.) Although the scientific literature unquestionably confirms the presence and activity of other psilocybin derivatives, those molecules have never been studied.
Both substances have an indirect effect on the brain chemical dopamine, commonly known as the “feel good” or “reward” drug in the brain. While this can foster motivation and drive during a trip, it can equally be cut by indecision or repetitive thoughts. As mentioned above, THC (found abundantly in Sativa strains) can boost and energize the sensations provided by the mushrooms; CBD (primarily in Indica strains) can calm a fast adventure or ease nausea and anxiety in beginners.
Mixing magic mushrooms and cannabis can produce an intensely psychedelic high characterised by abstract and thought-provoking visuals and sensations. Marijuana’s calming effects can dull the come-up of a mushroom trip, keeping you more relaxed during the early stages of the high. Moreover, some believe that consuming cannabis can lead to a more intense peak, and can even keep you more relaxed during the come-down stage.
Cannabis at the beginning of an experience can enhance the entirety, ease initial nausea, and remove any “rough transitions” that may arise while “coming up.” It can also help relieve anxiety or impatience associated with the relatively long duration of mushroom onset.
Once underway into the mushroom adventure, cannabis may seem unappealing to the average user, but experienced users can consider it to amplify the height of the sensations. Smoking can feel like a daunting undertaking, making the application of edibles at this point a viable alternative.
Past the peak, cannabis seems to enact its most potent synergy with magic mushrooms. Enhancing the already modified perception of time, the combination can greatly enhance the duration of lesser sensations and visuals. It can also help to damper any negative emotions that may accompany the waning hours of a trip. Finally, it can help slow thought and provide deeper context to contemplation of the recent experience.
Until recently, cannabis research and development focused almost entirely on a single molecule found in the plant — tetrahydrocannabinol (“THC”). THC was considered the only active ingredient. Based on this assumption, pharmaceutical companies developed products with pure THC, i.e., Dronabinol (aka Marinol or Syndros).
To date, psilocybin is still widely regarded as the only active and/or important molecule in magic mushrooms. The word “psilocybin” (a molecule) is used interchangeably with “magic mushrooms.” Just like early cannabis R&D, early movers in the magic mushroom space are focussing entirely on psilocybin to the exclusion of the other active molecules present in the mushroom.
Research has shown that both cannabis and (especially) psilocybin mushrooms are relatively safe and medically beneficial.
In the case of cannabis, this evidence has supported some recent changes to regulations and allowed for growth in that industry.
Despite a legacy of fear surrounding magic mushrooms, scientists have explicitly asserted that “Magic mushrooms are one of the safest drugs in the world.” Similar conclusions have led scientists at Johns Hopkins University to publish a thorough analysis, recommending that psilocybin should be rescheduled to one of the least restrictive categories of drugs.